News & Updates

Treatment with budesonide/glycopyrrolate/formoterol (BGF) using a metered dose inhaler (MDI) demonstrates an acceptable safety profile and improves symptoms in patients with chronic obstructive pulmonary disease (COPD) in a real-world clinical setting, results of the TORES study have shown.

Treatment with colchicine for 6 months when commencing urate-lowering therapy (ULT) provides no additional benefit in achieving gout remission regardless of the definition used, according to a study.

Use of anifrolumab improves symptoms and induces remission in patients with refractory systemic lupus erythematosus (SLE), with an acceptable safety profile, a study has shown.

Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.